Bakersfield, CA 93311
Reina Aesthetics
VisitPeptide therapy consultation
Published price$50
Consultation reservation fee; applied to a visit or treatment within 30 days
Care teamJulito Uy, MD
Medical director and physician
Peptides, GLP-1s and local care
Find care.
Know who’s behind it.
Compare clinics, prices and care teams before you book. Understand GLP-1 and peptide options with clear references and practical tools.
Healthspan Access
Find care near you.
Compare services, prices and care teams.
187 profiles across 63 cities
Search the reference
Inside a clinic profile
The details that make a decision easier.
Who you’ll see. What the visit costs. Where the information comes from. A clinic profile brings those details together before you book.
Explore the clinic network32peptide calculators
From your vial details
to syringe units.
Enter the amount in your vial, liquid volume and prescribed dose. See the draw for your syringe and the calculation behind it.
Open the peptide calculatorSame dose. Different draw.
U-100 syringeArithmetic example: 10 mg vial, 0.5 mg dose.
10 units
5 mg/mL concentration · 0.1 mL draw
Example numbers, not a recommended dose.
Compounds and comparisons.
Look up published doses and reported ranges, or see how two options differ.
Look up a compound
All 51 compoundsFind compounds by goal
These groups reflect why people look up a compound. Being listed under a goal does not mean a treatment is proven to help.
| Evidence group | Compounds |
|---|---|
| FDA-approved | 3 |
| Other human evidence | 9 |
| Reported use only | 3 |
Compare your options
Each comparison shows whether a trial tested the two options directly.
- Wegovy vs OzempicNo head-to-head trial
- Wegovy vs ZepboundSURMOUNT-5 · head-to-head trial
- Tirzepatide vs semaglutideSURMOUNT-5 · head-to-head trial
- GLP-1 pill vs injectionNo head-to-head trial
What the data changes.
Original analysis and the records behind it.
FDA side-effect reports · read
Dosing errors appear more often than nausea in these FDA reports.
An incorrect dose was reported in:
- 18% of Mounjaro reports
- 18% of Zepbound reports
These are shares of submitted reports, not estimates of a patient’s risk.
Read the analysis